- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Unmet Needs In Agitation Associated With Alzheimer’s Dementia

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Unmet Needs In Agitation Associated With Alzheimer’s Dementia
This is a Virtual Event for PsychU members in Arizona, Colorado, Nevada, New Mexico, Wyoming and El Paso, Texas.
This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis and explore the potential pathobiological correlations in AAD. Describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD.

Jessie Chambers, PhD
Medical Science Liaison

Laura Brennan, PhD (OPDC)
Medical Science Liaison
Speakers Jessie Chambers, PhD and Laura Brennan, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)